Trial ID or NCT#



recruiting iconRECRUITING


The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.

Official Title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of : Galcanezumab (LY2951742) With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Nada Hindiyeh, MD
Nada Hindiyeh, MD
Headache specialist
Clinical Associate Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


(650) 723-5184